Cancer Center Support Grant

癌症中心支持补助金

• 批准号: 10737660
• 负责人: Thomas James Lynch
• 金额: $ 19.44万
• 依托单位: FRED HUTCHINSON CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-01 至 2024-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10737660
• 关键词: Alaska; Area; Biology; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Detection; Cancer Etiology; Carcinogenesis Mechanism; Caregivers; Catchment Area; Cause of Death; Cessation of life; Child; Childhood; Clinical; Clinical Research; Collaborations; Communities; Comprehensive Cancer Center; Computational Biology; County; Development; Diagnosis; Diagnostic; Discipline; Disease; Educational process of instructing; Enrollment; Ensure; Equation; Equity; Exposure to; Faculty; Faculty Recruitment; Fostering; Funding; Genomics; Goals; Grant; Health; Health Sciences; Hematopoietic Stem Cell Transplantation; Idaho; Immunology; Immunotherapeutic agent; Individual; Institution; Intervention; Investments; Knowledge; Laboratories; Laboratory Research; Leadership; Malignant Neoplasms; Measures; Mentors; Mission; Molecular; Montana; Outcome; Patients; Peer Review; Population Research; Postdoctoral Fellow; Prevention; Prevention strategy; Primary Prevention; Public Health; Quality of Care; Research; Research Infrastructure; Research Personnel; Resources; Risk Factors; Risk Marker; Science; Secondary Prevention; Students; Therapeutic; Training; Training and Education; Translating; Translational Research; Translations; Transplantation; Underrepresented Populations; United States; Universities; Washington; Work; Wyoming; anticancer research; base; cancer care; cancer diagnosis; cancer therapy; carcinogenesis; clinical care; clinical practice; computer studies; epigenomics; graduate student; host neoplasm interaction; improved; insight; inter-institutional; interdisciplinary collaboration; interest; member; mortality; multidisciplinary; next generation; outreach; pathogen; profiles in patients; programs; synthetic biology; targeted treatment; therapy development; treatment center; treatment trial; tumor; tumor metabolism; tumor progression

PROJECT SUMMARY: OVERALL The Fred Hutchinson/University of Washington Cancer Consortium (“the Consortium”) brings together more than 600 members with research interests in basic, clinical and public health sciences related to cancer. The goal of the Consortium is the elimination of cancer as a cause of suffering and death through more effective prevention, diagnostics, and treatment, deriving from fundamental insights into the biology of the disease. The extensive interdisciplinary collaboration among the partner institutions in the cancer research disciplines of basic, clinical, and public health sciences affords new opportunities to reduce suffering and mortality from cancer. The Consortium was established in 2002 to build upon the complementary strengths and resources of three partner institutions: the Fred Hutch, which has been an NCI-designated Comprehensive Cancer Center since 1976; the University of Washington, which has significant strength in cancer research, clinical care, and teaching; and Seattle Children’s, the major pediatric academic center in the region. In 2008, the Seattle Cancer Care Alliance, the cancer treatment center founded and equally co-owned by the three founding institutions, was formally added to the cancer center designation. The Consortium’s total funding base (direct dollars) is $242M, of which $117M is peer-reviewed, including $50M from the NCI. During the last grant period, over 170 new faculty members joined the Consortium, adding breadth and depth to our research and clinical capabilities. In the most recent year, we enrolled 1,338 patients onto interventional treatment trials, of which more than 50% were investigator-initiated. The ratio of accruals to newly registered patients was 28%. The Consortium serves a catchment area of 13 counties in western Washington. This equates to the region in which 83 percent of our patients reside. As the only NCI-designated comprehensive cancer center in a five- state region (Washington, Wyoming, Alaska, Montana and Idaho), we not only seek to serve the health needs of the catchment area through research, training, and outreach, but also to ensure high impact throughout the larger region. The Consortium continues to build upon historic strengths in basic cancer biology, immunology and transplantation, pathogen associated malignancies, tumor specific translational research, computational biology and studies of cancer etiology, prevention, and outcomes. The Consortium is well poised to continue its exceptional level of research in these areas. The CCSG continues to have a high impact on the Consortium, fostering new inter-institutional collaborations, strengthening the translational research platform, and intensifying research efforts on problems of the catchment area. Partner institutions contributed nearly $1.2 billion in institutional support during the last project period, including investments in our laboratory and clinical research infrastructure as well as in faculty recruitment and trainee support.

项目总结：总体 弗雷德·哈钦森/华盛顿大学癌症联合会(The Consortium)汇集了更多 600多名成员，对与癌症有关的基础、临床和公共卫生科学有研究兴趣。这个 该联盟的目标是通过更有效的方法消除癌症作为痛苦和死亡的原因 预防、诊断和治疗，源于对疾病生物学的基本见解。这个 伙伴机构之间在#年癌症研究学科中的广泛跨学科合作 基础、临床和公共卫生科学提供了减少疾病痛苦和死亡率的新机会 癌症。 该联盟成立于2002年，旨在加强三家公司的优势和资源互补 合作机构：弗雷德·哈奇，自成立以来一直是NCI指定的综合癌症中心 1976年；华盛顿大学，在癌症研究、临床护理和 西雅图儿童中心，该地区主要的儿科学术中心。2008年，西雅图癌症 由三家创始机构共同拥有的癌症治疗中心CARE Alliance， 被正式添加到癌症中心名称中。 该联盟的总资金基数(直接美元)为2.42亿美元，其中1.17亿美元是同行审查的，包括 来自NCI的5000万美元。在上一次资助期间，超过170名新教员加入了该联盟，并补充说 我们的研究和临床能力的广度和深度。在最近一年，我们招募了1,338名患者 介入治疗试验，其中超过50%是由研究人员发起的。应计项目与应计项目的比率 新登记病人占28%。 该联盟为华盛顿州西部13个县的集水区提供服务。这等同于 其中83%的患者居住在这里。作为NCI指定的五年内唯一一家综合性癌症中心- 州地区(华盛顿州、怀俄明州、阿拉斯加州、蒙大拿州和爱达荷州)，我们不仅寻求服务于健康需求 通过研究、培训和推广，加强对集水区的影响，同时确保在整个 更大的区域。 该联盟继续在基础癌症生物学、免疫学和 移植，病原体相关恶性肿瘤，肿瘤特异性翻译研究，计算 生物学和癌症病因、预防和结果的研究。该财团已做好准备，将继续其 在这些领域的卓越研究水平。CCSG继续对财团产生很大影响， 促进新的机构间合作，加强翻译研究平台，以及 加大对集水区问题的研究力度。伙伴机构贡献了近1.2美元 在上一个项目期间提供了10亿美元的机构支持，包括对我们实验室和临床的投资 研究基础设施以及教师招聘和实习生支持。